Evaluation of a biphasic media assay for pyrazinamide drug susceptibility testing of Mycobacterium tuberculosis | Zendy

Ximena Gonzalo | Zendy; Francis Drobniewski | Zendy; Sven Hoffner | Zendy; Jim Werngren | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of a biphasic media assay for pyrazinamide drug susceptibility testing of Mycobacterium tuberculosis

Author(s) -

Ximena Gonzalo,

Francis Drobniewski,

Sven Hoffner,

Jim Werngren

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku230

Subject(s) - pyrazinamide , mycobacterium tuberculosis , tuberculosis , drug , microbiology and biotechnology , medicine , pharmacology , biology , pathology

Pyrazinamide is a key first-line tuberculosis drug. Reliable drug susceptibility testing (DST) data are of clinical importance, but in vitro testing is challenging since the activity of pyrazinamide is pH sensitive. The BACTEC MGIT 960 is considered the principal reference technique, but Wayne's test is an alternative, although it may be difficult to interpret. A further alternative is the use of a biphasic media assay (BMA). The objective of this work was to evaluate the BMA against the MGIT method and with screening of pncA gene mutations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research